Global Nonalcoholic Steatohepatitis (NASH) Market 2021 by Company, Regions, Type and Appl...

  • Report ID:49244
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94

Free Sample

Request Customization

Request A Callback

Enquiry before buying

 
                              

                               
The Nonalcoholic Steatohepatitis (NASH) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Nonalcoholic Steatohepatitis (NASH) size is estimated to be USD 13820 million in 2026 from USD 3152.9 million in 2020, with a change XX% between 2020 and 2021. The global Nonalcoholic Steatohepatitis (NASH) market size is expected to grow at a CAGR of 44.7% for the next five years.

Market segmentation
Nonalcoholic Steatohepatitis (NASH) market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Obeticholic acid?OCA?
    Selonsertib

Market segment by Application, can be divided into
    Hospital Pharmacy
    Online Provider
    Retail Pharmacy

Market segment by players, this report covers
    AstraZeneca
    Arena Pharmaceuticals
    GSK
    Novo Nordisk
    Roche
    Vivus
    Arisaph Pharmaceuticals
    Cempra Pharmaceuticals
    Galectin Therapeutics
    Galmed Pharmaceuticals
    Genfit
    Gilead

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Nonalcoholic Steatohepatitis (NASH) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Nonalcoholic Steatohepatitis (NASH), with revenue, gross margin and global market share of Nonalcoholic Steatohepatitis (NASH) from 2019 to 2021.
Chapter 3, the Nonalcoholic Steatohepatitis (NASH) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Nonalcoholic Steatohepatitis (NASH) market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Nonalcoholic Steatohepatitis (NASH) research findings and conclusion, appendix and data source.
                           

                       
                        

                         
1 Market Overview
    1.1 Product Overview and Scope of Nonalcoholic Steatohepatitis (NASH)
    1.2 Classification of Nonalcoholic Steatohepatitis (NASH) by Type
        1.2.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type in 2020
        1.2.3 Obeticholic acid?OCA?
        1.2.4 Selonsertib
    1.3 Global Nonalcoholic Steatohepatitis (NASH) Market by Application
        1.3.1 Overview: Global Nonalcoholic Steatohepatitis (NASH) Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Hospital Pharmacy
        1.3.3 Online Provider
        1.3.4 Retail Pharmacy
    1.4 Global Nonalcoholic Steatohepatitis (NASH) Market Size & Forecast
    1.5 Global Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast by Region
        1.5.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Region, (2016-2021)
        1.5.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2016-2026)
        1.5.4 Europe Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2016-2026)
        1.5.6 South America Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Nonalcoholic Steatohepatitis (NASH) Market Drivers
        1.6.2 Nonalcoholic Steatohepatitis (NASH) Market Restraints
        1.6.3 Nonalcoholic Steatohepatitis (NASH) Trends Analysis
2 Company Profiles
    2.1 AstraZeneca
        2.1.1 AstraZeneca Details
        2.1.2 AstraZeneca Major Business
        2.1.3 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.1.4 AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 AstraZeneca Recent Developments and Future Plans
    2.2 Arena Pharmaceuticals
        2.2.1 Arena Pharmaceuticals Details
        2.2.2 Arena Pharmaceuticals Major Business
        2.2.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.2.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 Arena Pharmaceuticals Recent Developments and Future Plans
    2.3 GSK
        2.3.1 GSK Details
        2.3.2 GSK Major Business
        2.3.3 GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.3.4 GSK Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 GSK Recent Developments and Future Plans
    2.4 Novo Nordisk
        2.4.1 Novo Nordisk Details
        2.4.2 Novo Nordisk Major Business
        2.4.3 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.4.4 Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Novo Nordisk Recent Developments and Future Plans
    2.5 Roche
        2.5.1 Roche Details
        2.5.2 Roche Major Business
        2.5.3 Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.5.4 Roche Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Roche Recent Developments and Future Plans
    2.6 Vivus
        2.6.1 Vivus Details
        2.6.2 Vivus Major Business
        2.6.3 Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.6.4 Vivus Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 Vivus Recent Developments and Future Plans
    2.7 Arisaph Pharmaceuticals
        2.7.1 Arisaph Pharmaceuticals Details
        2.7.2 Arisaph Pharmaceuticals Major Business
        2.7.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.7.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Arisaph Pharmaceuticals Recent Developments and Future Plans
    2.8 Cempra Pharmaceuticals
        2.8.1 Cempra Pharmaceuticals Details
        2.8.2 Cempra Pharmaceuticals Major Business
        2.8.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.8.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Cempra Pharmaceuticals Recent Developments and Future Plans
    2.9 Galectin Therapeutics
        2.9.1 Galectin Therapeutics Details
        2.9.2 Galectin Therapeutics Major Business
        2.9.3 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.9.4 Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Galectin Therapeutics Recent Developments and Future Plans
    2.10 Galmed Pharmaceuticals 
        2.10.1 Galmed Pharmaceuticals Details
        2.10.2 Galmed Pharmaceuticals Major Business
        2.10.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.10.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Galmed Pharmaceuticals Recent Developments and Future Plans
    2.11 Genfit
        2.11.1 Genfit Details
        2.11.2 Genfit Major Business
        2.11.3 Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.11.4 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Genfit Recent Developments and Future Plans
    2.12 Gilead
        2.12.1 Gilead Details
        2.12.2 Gilead Major Business
        2.12.3 Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
        2.12.4 Gilead Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Gilead Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Nonalcoholic Steatohepatitis (NASH) Players Market Share
        3.2.2 Top 10 Nonalcoholic Steatohepatitis (NASH) Players Market Share
        3.2.3 Market Competition Trend
    3.3 Nonalcoholic Steatohepatitis (NASH) Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Market Share by Type (2016-2021)
    4.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
    5.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2016-2021)
    5.2 Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
    6.1 North America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2026)
    6.2 North America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2026)
    6.3 North America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        6.3.1 North America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2026)
        6.3.2 United States Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        6.3.3 Canada Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        6.3.4 Mexico Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
    7.1 Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2026)
    7.2 Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2026)
    7.3 Europe Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        7.3.1 Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2026)
        7.3.2 Germany Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        7.3.3 France Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        7.3.5 Russia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        7.3.6 Italy Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2026)
    8.2 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2026)
    8.3 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Market Size by Region
        8.3.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Region (2016-2026)
        8.3.2 China Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        8.3.3 Japan Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        8.3.4 South Korea Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        8.3.5 India Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        8.3.7 Australia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
    9.1 South America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2026)
    9.2 South America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2026)
    9.3 South America Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        9.3.1 South America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2026)
        9.3.2 Brazil Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        9.3.3 Argentina Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2026)
    10.2 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2026)
    10.3 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Market Size by Country
        10.3.1 Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2026)
        10.3.2 Turkey Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
        10.3.4 UAE Nonalcoholic Steatohepatitis (NASH) Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer
Read More 
                

                 
List of Tables
    Table 1. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
    Table 2. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
    Table 3. Global Market Nonalcoholic Steatohepatitis (NASH) Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
    Table 4. Global Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) by Region (2016-2021)
    Table 5. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2021-2026)
    Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
    Table 7. AstraZeneca Major Business
    Table 8. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 9. AstraZeneca Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 10. Arena Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 11. Arena Pharmaceuticals Major Business
    Table 12. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 13. Arena Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 14. GSK Corporate Information, Head Office, and Major Competitors
    Table 15. GSK Major Business
    Table 16. GSK Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 17. GSK Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 18. Novo Nordisk Corporate Information, Head Office, and Major Competitors
    Table 19. Novo Nordisk Major Business
    Table 20. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 21. Novo Nordisk Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 22. Roche Corporate Information, Head Office, and Major Competitors
    Table 23. Roche Major Business
    Table 24. Roche Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 25. Roche Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 26. Vivus Corporate Information, Head Office, and Major Competitors
    Table 27. Vivus Major Business
    Table 28. Vivus Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 29. Vivus Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 30. Arisaph Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 31. Arisaph Pharmaceuticals Major Business
    Table 32. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 33. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 34. Cempra Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 35. Cempra Pharmaceuticals Major Business
    Table 36. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 37. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 38. Galectin Therapeutics Corporate Information, Head Office, and Major Competitors
    Table 39. Galectin Therapeutics Major Business
    Table 40. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 41. Galectin Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 42. Galmed Pharmaceuticals Corporate Information, Head Office, and Major Competitors
    Table 43. Galmed Pharmaceuticals Major Business
    Table 44. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 45. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 46. Genfit Corporate Information, Head Office, and Major Competitors
    Table 47. Genfit Major Business
    Table 48. Genfit Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 49. Genfit Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 50. Gilead Corporate Information, Head Office, and Major Competitors
    Table 51. Gilead Major Business
    Table 52. Gilead Nonalcoholic Steatohepatitis (NASH) Product and Solutions
    Table 53. Gilead Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million), Gross Margin and Market Share (2019-2021)
    Table 54. Global Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) by Players (2019-2021)
    Table 55. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players (2019-2021)
    Table 56. Breakdown of Nonalcoholic Steatohepatitis (NASH) by Company Type (Tier 1, Tier 2 and Tier 3)
    Table 57. Nonalcoholic Steatohepatitis (NASH) Players Head Office, Products and Services Provided
    Table 58. Nonalcoholic Steatohepatitis (NASH) Mergers & Acquisitions in the Past Five Years
    Table 59. Nonalcoholic Steatohepatitis (NASH) New Entrants and Expansion Plans
    Table 60. Global Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) by Type (2016-2021)
    Table 61. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Type (2016-2021)
    Table 62. Global Nonalcoholic Steatohepatitis (NASH) Revenue Forecast by Type (2021-2026)
    Table 63. Global Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021)
    Table 64. Global Nonalcoholic Steatohepatitis (NASH) Revenue Forecast by Application (2021-2026)
    Table 65. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2021) & (USD Million)
    Table 66. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2021-2026) & (USD Million)
    Table 67. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021) & (USD Million)
    Table 68. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2021-2026) & (USD Million)
    Table 69. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2021) & (USD Million)
    Table 70. North America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2021-2026) & (USD Million)
    Table 71. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2021) & (USD Million)
    Table 72. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2021-2026) & (USD Million)
    Table 73. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021) & (USD Million)
    Table 74. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2021-2026) & (USD Million)
    Table 75. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2021) & (USD Million)
    Table 76. Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2021-2026) & (USD Million)
    Table 77. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2021) & (USD Million)
    Table 78. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2021-2026) & (USD Million)
    Table 79. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021) & (USD Million)
    Table 80. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2021-2026) & (USD Million)
    Table 81. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Region (2016-2021) & (USD Million)
    Table 82. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Region (2021-2026) & (USD Million)
    Table 83. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2021) & (USD Million)
    Table 84. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2021-2026) & (USD Million)
    Table 85. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021) & (USD Million)
    Table 86. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2021-2026) & (USD Million)
    Table 87. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2021) & (USD Million)
    Table 88. South America Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2021-2026) & (USD Million)
    Table 89. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2016-2021) & (USD Million)
    Table 90. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Type (2021-2026) & (USD Million)
    Table 91. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2016-2021) & (USD Million)
    Table 92. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Application (2021-2026) & (USD Million)
    Table 93. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2016-2021) & (USD Million)
    Table 94. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Country (2021-2026) & (USD Million)
List of Figures
    Figure 1. Nonalcoholic Steatohepatitis (NASH) Picture
    Figure 2. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Type in 2020
    Figure 3. Obeticholic acid?OCA?
    Figure 4. Selonsertib
    Figure 5. Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application in 2020
    Figure 6. Hospital Pharmacy Picture
    Figure 7. Online Provider Picture
    Figure 8. Retail Pharmacy Picture
    Figure 9. Global Nonalcoholic Steatohepatitis (NASH) Revenue, (USD Million): 2020 VS 2021 VS 2026
    Figure 10. Global Nonalcoholic Steatohepatitis (NASH) Revenue and Forecast (2016-2026) & (USD Million)
    Figure 11. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2016-2026)
    Figure 12. Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region in 2020
    Figure 13. North America Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 14. Europe Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 15. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 16. South America Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 17. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Revenue (USD Million) and Growth Rate (2016-2026)
    Figure 18. Nonalcoholic Steatohepatitis (NASH) Market Drivers
    Figure 19. Nonalcoholic Steatohepatitis (NASH) Market Restraints
    Figure 20. Nonalcoholic Steatohepatitis (NASH) Market Trends
    Figure 21. AstraZeneca Recent Developments and Future Plans
    Figure 22. Arena Pharmaceuticals Recent Developments and Future Plans
    Figure 23. GSK Recent Developments and Future Plans
    Figure 24. Novo Nordisk Recent Developments and Future Plans
    Figure 25. Roche Recent Developments and Future Plans
    Figure 26. Vivus Recent Developments and Future Plans
    Figure 27. Arisaph Pharmaceuticals Recent Developments and Future Plans
    Figure 28. Cempra Pharmaceuticals Recent Developments and Future Plans
    Figure 29. Galectin Therapeutics Recent Developments and Future Plans
    Figure 30. Galmed Pharmaceuticals Recent Developments and Future Plans
    Figure 31. Genfit Recent Developments and Future Plans
    Figure 32. Gilead Recent Developments and Future Plans
    Figure 33. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Players in 2020
    Figure 34. Nonalcoholic Steatohepatitis (NASH) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    Figure 35. Global Top 3 Players Nonalcoholic Steatohepatitis (NASH) Revenue Market Share in 2020
    Figure 36. Global Top 10 Players Nonalcoholic Steatohepatitis (NASH) Revenue Market Share in 2020
    Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
    Figure 38. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Type in 2020
    Figure 39. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Type (2021-2026)
    Figure 40. Global Nonalcoholic Steatohepatitis (NASH) Revenue Share by Application in 2020
    Figure 41. Global Nonalcoholic Steatohepatitis (NASH) Market Share Forecast by Application (2021-2026)
    Figure 42. North America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2016-2026)
    Figure 43. North America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2016-2026)
    Figure 44. North America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Country (2016-2026)
    Figure 45. United States Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 46. Canada Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 47. Mexico Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 48. Europe Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2016-2026)
    Figure 49. Europe Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2016-2026)
    Figure 50. Europe Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Country (2016-2026)
    Figure 51. Germany Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 52. France Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 53. United Kingdom Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 54. Russia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 55. Italy Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 56. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2016-2026)
    Figure 57. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2016-2026)
    Figure 58. Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Region (2016-2026)
    Figure 59. China Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 60. Japan Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 61. South Korea Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 62. India Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 63. Southeast Asia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 64. Australia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 65. South America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2016-2026)
    Figure 66. South America Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2016-2026)
    Figure 67. South America Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Country (2016-2026)
    Figure 68. Brazil Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 69. Argentina Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 70. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Type (2016-2026)
    Figure 71. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Sales Market Share by Application (2016-2026)
    Figure 72. Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Country (2016-2026)
    Figure 73. Turkey Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 74. Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 75. UAE Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2016-2026) & (USD Million)
    Figure 76. Methodology
    Figure 77. Research Process and Data Source

Purchase Report

Single User 3480
Multi User 5220
Corporate User 6960
Buy

Speak To Analyst

Purchase Report

Customize the purchase as per your specific research needs:

  • 20% additional customization
  • Request for country level reports
  • Request for historical statistics
  • Additional company profile on request

Why Choose Our Report?

24/5 Research support

Get your queries resolved from an industry expert

Custom research service

Design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

Related Reports

Global IVD Infectious Disease Market Insights and Forecast to 2028
  • Report ID:183781
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94
  • 3480

Global Circulating Tumor Cells (CTC) Market Insights, Forecast to 2028
  • Report ID:185494
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94
  • 3480

Global Pigmentation Disorder Treatment Market Insights, Forecast to 2028
  • Report ID:185700
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94
  • 3480

Global Receptors Assay Market Insights, Forecast to 2028
  • Report ID:185866
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94
  • 3480

Global Single-Use Technologies for the Biologic Market Insights, Forecast to 2028
  • Report ID:186036
  • Industry Name: Medical Care
  • Publishing Date: Mar-21
  • No. of Pages: 94
  • 3480

clock

+1  347 708 0418

clocksales@acorinsights.com

trusted-site ssl paypal

COPYRIGHT © 2021 Acor Insights | All Rights Reserved.